Genetic Technologies Limited (: n/a)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | 0.00 |
---|---|
% Price Change (last 13 weeks): | 0.00 |
% Price Change (last 26 weeks): | -2.51 |
% Price Change (last 52 weeks): | -68.40 |
% Price Change (year to date): | -67.67 |
Return on Equity (%): | -182.02 |
---|---|
Return on Assets (%): | -112.33 |
Return on Invested Capital (%): | -83.79 |
Gross Profit Margin (%): | -54.41 |
---|---|
Net Profit Margin (%): | -156.78 |
Operating Profit Margin (%): | -164.14 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through the following segments: EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987, and is headquartered in Fitzroy, Australia.
|
Earnings (1year) ($): | -1.92 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.28 |
Cash Flow ($): | -1.71 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 1.31 |
Price/Book (x): | 5.37 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 0.83 |
---|---|
Current Ratio (x): | 0.88 |
LT Debt/Equity (x): | 1.25 |
Total Debt/Equity (x): | 47.81 |